Contract Research Associate - High Throughput Cellular Assays (6 Months)

Contract Research Associate - High Throughput Cellular Assays (6 Months)

Location: Boston

Monte Rosa Therapeutics is seeking a passionate Research Associate with the experience to implement and run complex cellular assays for a 6 month contract. This position is a key role in the pivotal team responsible for Automation and Screening Technologies & hits-to-leads support for Monte Rosa’s diverse pipeline. The ideal candidate will be able to help evolve Monte Rosa’s hit identification and hits-to-leads endeavors through embracing novel assay technologies, enhancing overall process and actively drive internal and external partnerships.

Principal Duties and Responsibilities:

• Perform a variety of molecular and cellular biology techniques, including mammalian cell culture, protein purification and Western blotting

• Implement and help to execute cell-based and biochemical assays using various technologies (e.g., fluorescence, luminescence, TR-FRET, AlphaScreen)

• Utilize automated liquid handling systems and laboratory robotics

• Analyze and interpret experimental data, compile results, and present findings to the team

• Maintain cell lines and prepare stock solutions

• Manage laboratory inventories and handle biohazardous materials according to safety protocols

• Ensure compliance with laboratory safety procedures and guidelines

Qualifications:

• Bachelor degree or equivalent in Biochemistry, Cell Biology or a life science with 1-2 years of industrial experience.

• Experience with mammalian cell culture and cell line generation. CRISPR experience is a plus.

• Proven track record for striving for high level of innovation and scientific excellence.

• Flexibility to accommodate to rapidly changing priorities and deadlines.

• Ability to work in a team-based environment.

• Excellent oral and written communication skills.

Interested candidates should forward CV and cover letter to careers-us@monterosatx.com or apply on line at www.monterosatx.com

Monte Rosa Therapeutics (MRT) is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.